# EDGAR Filing Document

**Accession Number:** 0001827635
**File Stem:** 0001628280-26-005240
**Filing Date:** 2026-2
**Character Count:** 11311
**Document Hash:** ff632d9922deaad1590a318511479676
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-005240.hdr.sgml**: 20260203

**ACCESSION NUMBER**: 0001628280-26-005240

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260203

**FILED AS OF DATE**: 20260203

**DATE AS OF CHANGE**: 20260203

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Durso Timothy August
- **CENTRAL INDEX KEY:** 0002107508

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43097
- **FILM NUMBER:** 26595713

**MAIL ADDRESS:**
- **STREET 1:** C/O VERADERMICS, INC.
- **STREET 2:** 470 JAMES STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06117
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Veradermics, Inc
- **CENTRAL INDEX KEY:** 0001827635
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 843304423
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 470 JAMES STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06513
- **BUSINESS PHONE:** 228.372.3376

**MAIL ADDRESS:**
- **STREET 1:** 470 JAMES STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06513

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VeraDermics, Inc
- **DATE OF NAME CHANGE:** 20201008

## Ex-24

**LIMITED POWER OF ATTORNEY**

The undersigned hereby constitutes and appoints Dominic Carrano, Michael Greco and Erika Sipperly, and each of them individually, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp;prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;execute for and on behalf of the undersigned, in the undersigned's capacity as officer and/or director of Veradermics, Incorporated (the "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;&nbsp;&nbsp;&nbsp;do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;&nbsp;&nbsp;&nbsp;take any other action of any type whatsoever in connection with the foregoing that, in the opinion of each such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by each such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as each such attorney-in-fact may approve in each such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or each such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that each foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D or 13G with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each foregoing attorney-in-fact.

[*Remainder of page intentionally left blank*]

------

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 3<sup>rd</sup> day of February, 2026.

---

| |
|:---|
| /s/ Tim Durso |
| Name: Tim Durso |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Durso Timothy August<br><sub>(Last) (First) (Middle)</sub><br>C/O VERADERMICS, INCORPORATED<br>470 JAMES ST.<br><sub>(Street)</sub><br>NEW HAVEN, CT 06513<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Veradermics, Inc [ MANE ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-03 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Technical Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 116717 | D |  |
| Common Stock | 116717 | I | By Durso Family Trust<sup>(1)</sup> |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Series A Convertible Preferred Stock | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 1473 | <sup>(2)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2026-12-12 | Common Stock | 3542 | $12.19 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2031-12-12 | Common Stock | 84504 | $12.19 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2027-12-21 | Common Stock | 3452 | $12.19 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2032-12-21 | Common Stock | 5343 | $12.19 | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2029-03-18 | Common Stock | 9864 | $12.19 | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2034-03-18 | Common Stock | 5035 | $12.19 | D |  |
| Stock Option (Right to Buy) | <sup>(5)</sup> | 2035-02-26 | Common Stock | 89699 | $12.19 | D |  |
| Stock Option (Right to Buy) | <sup>(6)</sup> | 2035-11-13 | Common Stock | 356689 | $12.79 | D |  |
| Stock Option (Right to Buy) | <sup>(7)</sup> | 2035-11-13 | Common Stock | 121992 | $12.79 | D |  |

---

### Footnotes:

(1) These shares are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

(2) Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis and has no expiration date. The Series A Convertible Preferred Stock will automatically convert into Common Stock immediately prior to the closing of the Issuer's initial public offering.

(3) This option is fully vested and exercisable as of the date hereof.

(4) The option is vested as to 33% of the underlying shares of Common Stock as of January 1, 2025, the first anniversary of the vesting commencement date, and vests as to the remaining shares in equal monthly installments over 24 months thereafter, subject to continued service.

(5) This option had a vesting start date of November 25, 2024 and vests in equal monthly installments over 48 months, beginning on the one-month anniversary of the vesting start date, subject to continued service.

(6) This option had a vesting start date of October 14, 2025 and vests in equal monthly installments over 48 months, beginning on the one-month anniversary of the vesting start date, subject to continued service.

(7) This option shall be fully vested and exercisable upon the certification by the Issuer's board of directors (or compensation committee thereof) that the Issuer has achieved a market capitalization of $680.0 million prior to December 31, 2026, subject to the reporting person's continued service. Market capitalization will be measured as the trading price per share of the Issuer's Common Stock on its principal market national stock exchange multiplied by the number of the Issuer's shares of Common Stock issued and outstanding.

**Remarks:**
Exhibit List: Exhibit 24 - Power of Attorney

**Signature:** /s/ Michael Greco, Attorney-in-Fact  
**Date:** 2026-02-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**